Clinical trial / 1984
Zinc gluconate lozenges reduced the average duration of common colds by about 7 days.
A double-blind, placebo-controlled clinical trial evaluated zinc gluconate lozenges (one 23-mg lozenge dissolved in the mouth every 2 wakeful hours after an initial double dose) versus matched placebo for treating common colds. After 7 days, 86% of 37 zinc-treated subjects were asymptomatic compared with 46% of 28 placebo-treated subjects (P = 0.0005). Overall, zinc lozenges shortened the average duration of common colds by about 7 days. Reported side effects were generally minor and mainly involved objectionable taste and mouth irritation.
- Study type
- Double-blind, placebo-controlled clinical trial
- Who was studied
- 65 subjects with common colds (37 zinc-treated, 28 placebo-treated)
- What was measured
- Resolution of cold symptoms (asymptomatic status at 7 days) and duration of cold
THE PAPER
Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study.
Eby GA, Davis DR, Halcomb WW. Antimicrob Agents Chemother, 1984.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.